PMID: 8612308Jan 1, 1996Paper

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase

Cancer Chemotherapy and Pharmacology
M BelanichD B Yarosh

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl adducts from DNA and may be important in tumor resistance to alkylation chemotherapy. MGMT was visualized in human cells and tumor tissues with monoclonal antibodies against MGMT and immunofluorescence microscopy, and fluorescent signals were quantified by digital image analysis. MGMT was found both in the cytoplasm and the nucleus, and in either locale the protein reacts with alkylated DNA bases and becomes inactivated and lost from the cell. Cell lines in culture and xenografts showed a broad normal distribution of nuclear MGMT levels, but human brain tumors often showed a skewed distribution, with a significant fraction of cells with high levels of MGMT. O(6)-Benzylguanine, a suicide substrate inactivator for MGMT activity, reduced MGMT in human cells and in a mouse xenograft to levels undetectable by antibody assay 1 h post-treatment. In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%. This quantitative immunofluorescence assay can be used to monitor MGMT and it depletion in human tumors to improve the use of alkylating agents in cancer chemotherapy.

Citations

May 7, 2013·Investigational New Drugs·Panagiotis J VlachostergiosChristos N Papandreou
Jun 2, 2009·Chemical Research in Toxicology·Rachel L LoeberNatalia Y Tretyakova
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jann N SarkariaWolfgang Wick
Nov 6, 2008·Expert Review of Anticancer Therapy·Enrico FranceschiAlba A Brandes
Jun 11, 2014·Nature Reviews. Neurology·Wolfgang WickGuido Reifenberger
May 4, 2005·Current Neurology and Neuroscience Reports·Roger StuppMonika E Hegi
Mar 31, 2015·Seminars in Cancer Biology·Dass S VinayByoung S Kwon
Jul 13, 2002·Expert Review of Anticancer Therapy·G J KitangeR B Jenkins
Jun 28, 2008·Cancer Investigation·Lucienne Juillerat-JeanneretRobert C Janzer
Jun 3, 2015·International Journal of Oncology·Giulio CabriniRoberto Gambari
Oct 27, 2009·Pediatric Blood & Cancer·Sabrina SchlosserMichael C Frühwald
Apr 12, 2003·Neuroimaging Clinics of North America·Sridharan Gururangan, Henry S Friedman
Mar 31, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Asia AsiafMohammad Afzal Zargar
Feb 15, 2007·Expert Opinion on Therapeutic Targets·Alexandre Juillerat, Lucienne Juillerat-Jeanneret
Apr 9, 2015·BMC Cancer·Sangeetha Sukumari-RameshKrishnan M Dhandapani
Jul 18, 2016·Journal of the Neurological Sciences·Guo-Zhong YiSong-Tao Qi
Sep 28, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francesco MarchesiLiana De Vecchis
Sep 28, 2010·Neuro-Chirurgie·D Fontaine, P Paquis
Apr 26, 2007·The American Journal of Pathology·Hiroko Ohgaki, Paul Kleihues
Mar 1, 2005·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Tülay AkçayDerin Kösebay
Dec 7, 2002·Nature Biotechnology·Antje KepplerKai Johnsson
Apr 2, 2004·Nature Reviews. Cancer·Stanton L Gerson
Apr 1, 1997·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·R KochharS N Thibodeau
Apr 21, 2017·Journal of Neuro-oncology·Er NieYongping You
Nov 18, 2005·Journal of Neuro-oncology·A RuggieroR Riccardi
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Noboru KonishiKazutake Tsujikawa
Sep 2, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GanderM D'Incalci

❮ Previous
Next ❯